Management of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2014 Oct 17

PMID 25320018

Citations 4

Authors

Manreet Kanwar

Ryan J Tedford

Richa Agarwal

Megan M Clarke

Claire Walter

George Sokos

Srinivas Murali

Raymond L Benza

Affiliations

Soon will be listed here.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.

Citing Articles

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors.

Ovchinnikov A, Potekhina A, Belyavskiy E, Ageev F Pharmaceuticals (Basel). 2022; 15(8).

PMID: 36015172 PMC: 9414416. DOI: 10.3390/ph15081024.

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF.

Barilli M, Tavera M, Valente S, Palazzuoli A Int J Mol Sci. 2022; 23(9).

PMID: 35562945 PMC: 9103781. DOI: 10.3390/ijms23094554.

Pulmonary arterial hypertension and heart failure with preserved ejection fraction: are they so discordant?.

Ruocco G, Gavazzi A, Gonnelli S, Palazzuoli A Cardiovasc Diagn Ther. 2020; 10(3):534-545.

PMID: 32695633 PMC: 7369277. DOI: 10.21037/cdt-19-405.

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Samson R, Jaiswal A, Ennezat P, Cassidy M, Le Jemtel T J Am Heart Assoc. 2016; 5(1).

PMID: 26811159 PMC: 4859363. DOI: 10.1161/JAHA.115.002477.

References

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

Thadani U, PARKER J . Hemodynamics at rest and during supine and sitting bicycle exercise in normal subjects. Am J Cardiol. 1978; 41(1):52-9. DOI: 10.1016/0002-9149(78)90131-5. View

Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S . Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002; 105(20):2398-403. DOI: 10.1161/01.cir.0000016641.12984.dc. View

Borlaug B, Lam C, Roger V, Rodeheffer R, Redfield M . Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009; 54(5):410-8. PMC: 2753478. DOI: 10.1016/j.jacc.2009.05.013. View

Prasad A, Hastings J, Shibata S, Popovic Z, Arbab-Zadeh A, Bhella P . Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail. 2010; 3(5):617-26. PMC: 3716372. DOI: 10.1161/CIRCHEARTFAILURE.109.867044. View

Noguchi T, Kihara Y, Begin K, Gorga J, Palmiter K, LeWinter M . Altered myocardial thin-filament function in the failing Dahl salt-sensitive rat heart: amelioration by endothelin blockade. Circulation. 2003; 107(4):630-5. DOI: 10.1161/01.cir.0000046267.16901.e9. View

Luo C, Ramachandran D, Ware D, Ma T, Clark Jr J . Modeling left ventricular diastolic dysfunction: classification and key indicators. Theor Biol Med Model. 2011; 8:14. PMC: 3117805. DOI: 10.1186/1742-4682-8-14. View

Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O . RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol. 2003; 41(2):204-10. DOI: 10.1016/s0735-1097(02)02708-0. View

Francis S, Blount M, Corbin J . Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011; 91(2):651-90. DOI: 10.1152/physrev.00030.2010. View

10.

Yusuf S, Pfeffer M, Swedberg K, Granger C, Held P, McMurray J . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386):777-81. DOI: 10.1016/S0140-6736(03)14285-7. View

11.

Thenappan T, Shah S, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P . Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011; 4(3):257-65. DOI: 10.1161/CIRCHEARTFAILURE.110.958801. View

12.

McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur Heart J. 2012; 33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. View

13.

Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S . Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest. 2013; 145(5):1064-1070. DOI: 10.1378/chest.13-1510. View

14.

Deboeck G, Taboada D, Hagan G, Treacy C, Page K, Sheares K . Maximal cardiac output determines 6 minutes walking distance in pulmonary hypertension. PLoS One. 2014; 9(3):e92324. PMC: 3960234. DOI: 10.1371/journal.pone.0092324. View

15.

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

16.

Vuurmans T, Boer P, Koomans H . Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension. 2003; 41(6):1253-8. DOI: 10.1161/01.HYP.0000072982.70666.E8. View

17.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):1810-52. DOI: 10.1161/CIR.0b013e31829e8807. View

18.

Klapholz M, Maurer M, Lowe A, Messineo F, Meisner J, Mitchell J . Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004; 43(8):1432-8. DOI: 10.1016/j.jacc.2003.11.040. View

19.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

20.

Lam C, Roger V, Rodeheffer R, Borlaug B, Enders F, Redfield M . Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009; 53(13):1119-26. PMC: 2736110. DOI: 10.1016/j.jacc.2008.11.051. View